CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Which index type is best for passive investing? This guide compares index types, costs, and tracking performance to help you pick the most efficient option.
23,556 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
SpaceX's planned IPO has drawn record demand, but market watchers warn buyers to scrutinize the order book for true d...
The SEC has proposed scrapping Rule 611 and Rule 610(e), a step that could transform tokenized US stocks trading in D...
A convincing fake bank call sent a Virginia resident on a cash handoff, revealing how scammers use authority and urge...
Alphabet blew past expectations with a robust earnings beat and a cloud backlog that leapt to $460 billion, signaling...
The shift in AI spending is reshaping winners and losers. This article explains why a power-semiconductor-focused com...
A new funding framework could let Ethereum validators redirect up to 10% of staking rewards to ecosystem projects, bu...
An AI-backed forecast tied to Sam Altman’s ChatGPT points to SpaceX stock climbing into the mid-to-high $200s by end-...
A statewide pattern shows elder fraud couriers siphoning millions from dozens of seniors. This guide explains how the...
Caregiving and end-of-life decisions test both hearts and wallets. This article explores practical, compassionate ste...
A familiar theme in energy investing is volatility followed by opportunity. This nuclear energy stock has recently fa...
A workspace platform popular in AR/VR opens a funding round at $0.79 per share, boasting 1.5m people already work ins...